-
Sanofi completes closing of collaborative agreement with Janssen to develop & commercialize vaccine candidate for extraintestinal pathogenic?E.?coli
10 Nov 2023 04:14 GMT
Sanofi announces completion of closing for its collaborative agreement with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company to develop and commercialize the vaccine candidate for extraintestinal pathogenic?E.?coli?(9-valent) ( …
-
Cough syrup recall: What is diethylene glycol and what happens when you drink it?
15 Apr 2024 13:37 GMT
At the weekend the South African Health Products Regulatory Authority (SAHPRA) recalled a popular over-the-counter cough syrup, Benylin Paediatric Syrup. The recall means that retailers, doctors and hospitals must stop dispensing the medicine immediately. …
-
Sanofi enters agreement with Janssen to develop & commercialise vaccine candidate for extraintestinal pathogenic E. coli
04 Oct 2023 03:48 GMT
Sanofi announces that it has entered into an agreement with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company, to develop and commercialize the vaccine candidate for extraintestinal pathogenic E. coli (9-valent) developed by Janssen, …
-
J&J, retreating from infectious disease, partners with Sanofi on E. coli vaccine
03 Oct 2023 19:54 GMT
Dive Brief:
Sanofi has agreed to work with Johnson & Johnson on what could be the first vaccine against a deadly strain of E. coli.
J&J developed the vaccine, now in Phase 3 testing, to fight extraintestinal pathogenic E. coli, a leading cause of …
-
Sanofi-Janssen collaboration to advance novel E. coli vaccine
03 Oct 2023 17:38 GMT
A potential first-in-class extraintestinal pathogenic E. coli (ExPEC) vaccine set to be jointly developed by Sanofi and Janssen, could help to abate a pathogen that is key in driving global antimicrobial resistance (AMR).
Sanofi and Janssen Pharmaceuticals …
-
Sanofi and Janssen join forces to develop E.coli vaccine, with Sanofi's $175M upfront payment
03 Oct 2023 16:47 GMT
Check out what's clicking on FoxBusiness.com
Sanofi on Tuesday announced it had reached an agreement with Janssen, a part of Johnson & Johnson, to develop and commercialize a vaccine candidate for extra-intestinal pathogenic E.coli.
The logo of …
-
Sanofi, Janssen Enter E.coli Vax Pact
03 Oct 2023 15:16 GMT
Breaking News
To develop and commercialize Janssen's Phase 3 vaccine candidate for extraintestinal pathogenic E.coli (9-valent).
10.03.23
Sanofi has entered into an agreement with Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, to …
-
Pharma Giants Sanofi, Johnson & Johnson Join Forces To Develop E.coli Vaccine
03 Oct 2023 13:14 GMT
Sanofi SA SNY struck a deal with Janssen Pharmaceuticals, a unit of Johnson & Johnson JNJ, to develop and commercialize the vaccine candidate for extraintestinal pathogenic E. coli (9-valent).
The vaccine is currently in Phase 3 E.mbrace trial designed …
-
Sanofi enters agreement with Janssen to develop E. coli vaccine candidate
03 Oct 2023 12:32 GMT
Sanofi has reached an agreement to develop and commercialise an experimental vaccine candidate for extraintestinal pathogenic E. coli developed by Janssen Pharmaceuticals.
Under the terms of the deal, Sanofi will pay the Johnson & Johnson unit $175m …
-
Sanofi Clinches Vaccine Deal With J&J to Battle E. Coli
03 Oct 2023 10:06 GMT
(Bloomberg) -- Sanofi struck a deal to help fund and sell an experimental vaccine developed by Johnson & Johnson against an invasive form of the digestive pathogen E. coli.
Sanofi will pay J&J’s Janssen unit $175 million upfront, as well as …